YOKNEAM, Israel, Nov. 30 /PRNewswire-FirstCall/ -- Lumenis(R) Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light- based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today that it has signed a purchase agreement with Corporacion Dermoestetica, the largest medical aesthetic organization in Europe, for the sale of 50 IPL Quantum systems.
“The commercial relationship and professional cooperation between Lumenis and Corporacion Dermoestetica started many years ago. This latest purchase is one more in a series that have strengthened both companies in the European market,” commented Amnon Harari, Vice President of European Sales and Service. “To maintain their leadership position as the most advanced medical aesthetic organization in Europe, Corporacion Dermoestetica strives to continually improve their treatment alternatives by investing in the most up-to-date technology. As the world market leader in medical lasers and light-based technology, Lumenis offers precisely what Corporacion Dermoestetica needs.”
Mr. Jose Maria Suescun, the President of Corporacion Dermoestetica, said, “We have chosen Lumenis because of our existing working relationship, as well as its industry expertise and innovative technology. The decision to invest in 50 additional IPL Quantum systems is based on our own positive experience with this “work horse” and field-proven system. As the market leader in European medical aesthetic clinics, it is only natural that we turn to the global market leader in this technology to equip us as we continue to upgrade and expand to meet the growing needs in our European market. We are extremely confident in Lumenis technologies.”
With the installation of these 50 new IPL Quantum units, Corporacion Dermoestetica will have over 200 Lumenis laser systems installed in their clinics throughout Europe. Some of the new systems are intended to replace older Lumenis systems as well as replace competitor systems used by Corporacion Dermoestetica. Additional units will be installed in new clinics expected to open in the coming months.
About Corporacion Dermoestetica
Corporacion Dermoestetica is a leading medical aesthetic organization founded in Spain in 1979, to offer a complete range of services and specialties within the aesthetic sector. Currently, with 90 wholly-owned clinics throughout Spain, Portugal, Italy and the United Kingdom, the company continues to expand to meet the needs in the European market. Corporacion Dermoestetica, currently the most advanced medical aesthetic organization in Europe, strives to continually improve its treatment alternatives by investing in the most up-to-date technology. For more information about Corporacion Dermoestetica and its services, log onto http://www.corporaciondermoestetica.com
About Lumenis
Lumenis is a global developer, manufacturer and seller of laser and light- based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto http://www.lumenis.com
Investors:
Lauri Hanover 1-866-232-6803, +972-4-959-9122
The statements in this press release that are not historical facts are forward-looking statements which are subject to risks and uncertainties. The Company’s actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company’s products, the implementation and outcome of our Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company’s international operations and the Company’s ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation (including the Wells Notice recently received in which the staff indicated its intention to recommend that a civil proceeding be brought seeking, among other things, injunctive relief and civil monetary penalties) and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company’s continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.
Lumenis Ltd.
CONTACT: Investors, Lauri Hanover, 1-866-232-6803, +972-4-959-9122
